Possibilities of IFN-free therapy of hepatitis C
Chronic hepatitis C therapy using Directly Acting Antivirals (DAA) has high efficacy (till 100 %), minimum contra-indications and extraordinarily favorable safety profile. Primarily, it is necessary to pay attention to drug-drug interactions. However they are well documented and successfully resolvable already in general clinical practice. Current possibilities of interferon-free therapy represent combinations of sofosbuvir with other DAA or with ribavirin and combination of paritaprevir boosted by ritonavir+ombitasvir±dasabuvir (3D combination)..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:61 Suppl 4 |
|---|---|
| Enthalten in: |
Vnitřnı lékařství - 61 Suppl 4(2015), Seite 4s24 |
| Sprache: |
Tschechisch |
|---|
| Beteiligte Personen: |
Husa, Petr [VerfasserIn] |
|---|
| Links: |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
OLC1962136078 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1962136078 | ||
| 003 | DE-627 | ||
| 005 | 20230508123453.0 | ||
| 007 | tu | ||
| 008 | 160206s2015 xx ||||| 00| ||cze c | ||
| 028 | 5 | 2 | |a PQ20160617 |
| 035 | |a (DE-627)OLC1962136078 | ||
| 035 | |a (DE-599)GBVOLC1962136078 | ||
| 035 | |a (PRQ)pubmed_primary_266676170 | ||
| 035 | |a (KEY)N0524285420150000061000000004possibilitiesofifnfreetherapyofhepatitisc | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a cze | ||
| 082 | 0 | 4 | |a 610 |q DNB |
| 100 | 1 | |a Husa, Petr |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Possibilities of IFN-free therapy of hepatitis C |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Chronic hepatitis C therapy using Directly Acting Antivirals (DAA) has high efficacy (till 100 %), minimum contra-indications and extraordinarily favorable safety profile. Primarily, it is necessary to pay attention to drug-drug interactions. However they are well documented and successfully resolvable already in general clinical practice. Current possibilities of interferon-free therapy represent combinations of sofosbuvir with other DAA or with ribavirin and combination of paritaprevir boosted by ritonavir+ombitasvir±dasabuvir (3D combination). | ||
| 773 | 0 | 8 | |i Enthalten in |t Vnitřnı lékařství |d Praha : Česká Lékařská Společnost Jana Evangelisty Purkyně, 1955 |g 61 Suppl 4(2015), Seite 4s24 |w (DE-627)166267376 |w (DE-600)138213-5 |w (DE-576)014611228 |x 0042-773X |7 nnns |
| 773 | 1 | 8 | |g volume:61 Suppl 4 |g year:2015 |g pages:4s24 |
| 856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/26667617 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_4219 | ||
| 951 | |a AR | ||
| 952 | |d 61 Suppl 4 |j 2015 |h 4s24 | ||